Top

Published in:

01-05-2012 | Case Report

Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy

Authors: Yoshitomo Kajino, Tamon Kabata, Koji Watanabe, Hiroyuki Tsuchiya

Published in: Journal of Orthopaedic Science | Issue 3/2012

Excerpt

Drug therapy for osteoporosis is widely accepted. Bisphosphonates in particular significantly inhibit bone resorption by suppressing osteoclast activity and increasing bone density [1‐3]. Alendronate is one of these bisphosphonates; it was approved in the United States in the 1990s and is commonly prescribed worldwide [1, 4, 5]. Clinical trials have shown its effectiveness in the treatment of fractures related to postmenopausal osteoporosis [6]. However, some recent reports have described unusual subtrochanteric or femoral shaft fractures following long-term alendronate therapy [4, 7‐13]. Although no causal relationship between long-term alendronate treatment and these atypical stress fractures has been established, some reports suggest that the severe suppression of bone turnover by alendronate may lead to accumulated microdamage to the bone that subsequently results in complete fracture [4, 12]. …

Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase III Osteoporosis Treatment Study Group. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–99.PubMedCrossRef

Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45.PubMedCrossRef

Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1555–65.PubMedCrossRef

Sayed-Noor AS, Sjödén GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009;467(7):1921–6.PubMedCrossRef

Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med. 2010;362(19):1825–7.PubMedCrossRef

Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med. 2009;122(2 Suppl):S14–21.PubMedCrossRef

Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res. 2010;468(7):1991–6.PubMedCrossRef

Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89(3):349–53.PubMedCrossRef

Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39(2):224–31.PubMedCrossRef

10.

Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358(12):1304–6.PubMedCrossRef

11.

Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–301.PubMedCrossRef

12.

Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf). 2010;72(2):161–8.CrossRef

13.

Somford MP, Geurts GF, den Teuling JW, Thomassen BJ, Draijer WF. Long-term alendronate use not without consequences? Int J Rheumatol. 2009.

14.

Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–41.PubMedCrossRef

15.

Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis. N Engl J Med. 2008;359(3):316–7.PubMedCrossRef

16.

Japanese Guidelines for the Prevention and Treatment of Osteoporosis 2006 edition. Life Science Publishing, Tokyo, 2006:73–102 (in Japanese).

17.

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M, American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94.PubMedCrossRef

18.

Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br. 2010;92(5):679–86.PubMedCrossRef

19.

Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24(10):1736–40.PubMedCrossRef

20.

Lee P, Seibel MJ. More on atypical fractures of the femoral diaphysis. N Engl J Med. 2008;359(3):317.PubMed

21.

Sims SH. Subtrochanteric femur fractures. Orthop Clin North Am. 2002;33(1):113–26.PubMedCrossRef

22.

Online version of Gray’s anatomy. Available at http://www.bartleby.com/107/59.html. Accessed Oct 20, 2010.

23.

Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15(4):613–20.PubMedCrossRef

24.

Medicines and Healthcare Products Regulatory Agency (MHRA). Bisphosphonate: atypical stress fractures. Drug safety update 2 (8). Available at http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON041211. Accessed Oct 13, 2010.

25.

Lin JH, Duggan DE, Chen IW, Ellsworth RL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos. 1991;19(5):926–32.PubMed

26.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, LE Wehren, Lombardi A, Santora AC, Cummings SR, FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–38.PubMedCrossRef

27.

Noth I, Strek ME, Leff AR. Churg–Strauss syndrome. Lancet. 2003;361:587–94.PubMedCrossRef

28.

Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24(6):1095–102.PubMedCrossRef

29.

Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC, Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761–71.PubMedCrossRef

30.

Dobnig H, Stepan JJ, Burr DB, Li J, Michalská D, Sipos A, Petto H, Fahrleitner-Pammer A, Pavo I. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res. 2009;24(12):1998–2006.PubMedCrossRef

Title: Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy
Authors: Yoshitomo Kajino
Tamon Kabata
Koji Watanabe
Hiroyuki Tsuchiya
Publication date: 01-05-2012
Publisher: Springer Japan
Published in: Journal of Orthopaedic Science / Issue 3/2012
Print ISSN: 0949-2658
Electronic ISSN: 1436-2023
DOI: https://doi.org/10.1007/s00776-011-0085-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2012

Effect of Epimedium pubescen flavonoid on bone mineral density and biomechanical properties of femoral distal end and femoral diaphysis of passively smoking male rats

High prevalence of acetabular retroversion in both affected and unaffected hips after Legg-Calvé-Perthes disease

Pain distribution and response to total hip arthroplasty: a prospective observational study in 113 patients with end-stage hip disease

Establishment of an animal model for delayed-onset muscle soreness after high-intensity eccentric exercise and its application for investigating the efficacy of low-load eccentric training

The influence of body mass index on life quality and clinical improvement after total hip arthroplasty

Surgical site infection and malignant soft tissue tumors